Pronutria Biosciences Announces Issuance of Key Patents from USPTO on Compositions and Methods Relating to Oral Biologics

Pronutria Biosciences Announces Issuance of Key Patents from USPTO on Compositions and Methods Relating to Oral Biologics

December 18, 2014

Granted claims include composition of matter on lead products

CAMBRIDGE, Mass., Dec. 18, 2014 /PRNewswire/ -- Pronutria Biosciences, Inc., which is developing novel oral biologics to restore cellular homeostasis in a range of serious medical conditions, today announced the issuance by the United States Patent and Trademark Office (USPTO) of US Patent No. 8,809,259 and US Patent No. 8,822,412. The patents claim proteins and methods of their use covering the company's lead product candidates, including PN-107 and PN-340.

Quanterix Announces the Simoa Accelerator, an Innovation Center for Biomarker Research and Custom Assay Development

Quanterix Announces the Simoa Accelerator, an Innovation Center for Biomarker Research and Custom Assay Development

December 16, 2014

LEXINGTON, Mass.--()--Quanterix Corp

Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

December 16, 2014

CAMBRIDGE, Mass.Dec.

Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors

Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors

December 12, 2014

 CAMBRIDGE, Mass.--()--Acceleron Pharma Inc.

Syros Pharmaceuticals Announces New Research Published on CDK7 in Lung and Pediatric Cancers

Syros Pharmaceuticals Announces New Research Published on CDK7 in Lung and Pediatric Cancers

December 11, 2014

- Papers in Cell and Cancer Cell describe in vivo activity of CDK7 inhibitors; further validate company’s lead preclinical program -

WATERTOWN, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today the recent publication of two studies that further demonstrate the critical role of CDK7 in cancers driven by oncogenic transcription factors, including certain lung and pediatric cancers.

Syros Pharmaceuticals Presents New Data from Its Gene Control Platform at Oncology Conferences

Syros Pharmaceuticals Presents New Data from Its Gene Control Platform at Oncology Conferences

December 11, 2014

- Posters at 56th ASH Annual Meeting and 2014 San Antonio Breast Cancer Symposium highlight identification of patient subtypes and novel drug targets in acute myeloid leukemia and breast cancer -

Concert Pharmaceuticals Names Thomas Auchincloss to Board of Directors and Chair of the Audit Committee

Concert Pharmaceuticals Names Thomas Auchincloss to Board of Directors and Chair of the Audit Committee

December 10, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc

Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors

Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors

December 10, 2014

CAMBRIDGE, Mass.Dec.

Symbiota Appoints International Plant Sciences Leader Dr. Roger Beachy to its Board of Directors

Symbiota Appoints International Plant Sciences Leader Dr. Roger Beachy to its Board of Directors

December 10, 2014

CAMBRIDGE, Mass., December 10, 2014 /PRNewswire/ — Symbiota™, pioneer of plant microbiome solutions that naturally promote plant health and improve agricultural production, today announced the key addition of Dr. Roger Beachy to its board of directors.

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update

December 9, 2014

DUBLIN & LEXINGTON, Mass.--()--Jazz